Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease
- PMID: 34508923
- DOI: 10.1016/j.npep.2021.102196
Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease
Abstract
Alzheimer's disease (AD) isaprogressive neurodegenerative disorder characterized by chronic inflammation due to the presence of neurotoxic Aβ and tau proteins. Increased microglial activation and inflated immune response are the other factors to be considered in AD pathology. Microglial cells own biochemical machinery that synthesizes and release endocannabinoids. The exploitation of therapeutic actions of endocannabinoid system has newly emerged in the field of Alzheimer's disease. The activation of cannabinoid receptors/ cannabinoid system modulates inflammatory responses. This review assesses the association between the microglial endocannabinoid system and neuroinflammation in AD. The data supporting the anti-inflammatory role of pharmacological agents modulating cannabinoid system are also reviewed.
Keywords: Alzheimer's disease; CB(1)R; CB(2)R; Endocannabinoid; Microglia; Neuroinflammation.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Therapeutic potential of plant-derived natural compounds in Alzheimer's disease: Targeting microglia-mediated neuroinflammation.Biomed Pharmacother. 2024 Sep;178:117235. doi: 10.1016/j.biopha.2024.117235. Epub 2024 Aug 1. Biomed Pharmacother. 2024. PMID: 39094545 Review.
-
Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials.J Neurosci Res. 2021 Nov;99(11):2888-2905. doi: 10.1002/jnr.24933. Epub 2021 Sep 6. J Neurosci Res. 2021. PMID: 34486749 Review.
-
Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches.Molecules. 2024 Mar 26;29(7):1478. doi: 10.3390/molecules29071478. Molecules. 2024. PMID: 38611758 Free PMC article. Review.
-
Microglial Endocannabinoid Signalling in AD.Cells. 2022 Apr 6;11(7):1237. doi: 10.3390/cells11071237. Cells. 2022. PMID: 35406803 Free PMC article. Review.
-
Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer's Disease.Int J Mol Sci. 2024 Apr 5;25(7):4050. doi: 10.3390/ijms25074050. Int J Mol Sci. 2024. PMID: 38612861 Free PMC article. Review.
Cited by
-
Interplay Between Astroglial Endocannabinoid System and the Cognitive Dysfunction in Alzheimer's Disease.Physiol Res. 2023 Nov 28;72(5):575-586. doi: 10.33549/physiolres.935156. Physiol Res. 2023. PMID: 38015757 Free PMC article. Review.
-
Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies.Front Pharmacol. 2023 Mar 3;14:1053680. doi: 10.3389/fphar.2023.1053680. eCollection 2023. Front Pharmacol. 2023. PMID: 36959856 Free PMC article.
-
Are Oligodendrocytes the Culprits or Victims in Alzheimer's Disease.Physiol Res. 2025 Apr 30;74(2):219-231. doi: 10.33549/physiolres.935451. Physiol Res. 2025. PMID: 40432437 Free PMC article. Review.
-
A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects.Inflammopharmacology. 2023 Apr;31(2):673-688. doi: 10.1007/s10787-023-01192-2. Epub 2023 Mar 24. Inflammopharmacology. 2023. PMID: 36961665 Review.
-
Differential Effects of Endocannabinoids on Amyloid-Beta Aggregation and Toxicity.Int J Mol Sci. 2023 Jan 4;24(2):911. doi: 10.3390/ijms24020911. Int J Mol Sci. 2023. PMID: 36674424 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical